BACKGROUND AND OBJECTIVE: Quality prescribing for older adults involves multiple considerations. We evaluated multiple aspects of prescribing quality in older veterans to develop an integrated view of prescribing problems and to understand how the prevalence of these problems varies across clinically important subgroups of older adults. DESIGN AND PARTICIPANTS: Cross-sectional observational study of veterans age 65 years and older who received medications from Department of Veterans Affairs (VA) pharmacies in 2007. MAIN MEASURES: Using VA pharmacy data linked with encounter, laboratory and other data, we assessed five types of prescribing problems. KEY RESULTS: Among 462,405 patients age 65 and older, mean age was 75 years, 98 % were male, and patients were prescribed a median of five medications. Half of patients (50 %) had one or more prescribing problems, including 12 % taking one or more medications at an inappropriately high dose, 30 % with drug-drug interactions, 3 % with drug-disease interactions, and 26 % taking one or more Beers criteria drugs. In addition, 16 % were taking a high-risk drug (warfarin, insulin, and/or digoxin). On multivariable analysis, age was not strongly associated with four of the five types of prescribing issues assessed (relative risk < 1.3 across age groups), and comorbid burden conferred substantially increased risk only for drug-disease interactions and use of high-risk drugs. In contrast, the number of drugs used was consistently the strongest predictor of prescribing problems. Patients in the highest quartile of medication use had 6.6-fold to12.5-fold greater risk of each type of prescribing problem compared to patients in the lowest quartile (P < 0.001 for each). CONCLUSIONS: The number of medications used is by far the strongest risk factor for each of five types of prescribing problems. Efforts to improve prescribing should especially target patients taking multiple medications.
BACKGROUND AND OBJECTIVE: Quality prescribing for older adults involves multiple considerations. We evaluated multiple aspects of prescribing quality in older veterans to develop an integrated view of prescribing problems and to understand how the prevalence of these problems varies across clinically important subgroups of older adults. DESIGN AND PARTICIPANTS: Cross-sectional observational study of veterans age 65 years and older who received medications from Department of Veterans Affairs (VA) pharmacies in 2007. MAIN MEASURES: Using VA pharmacy data linked with encounter, laboratory and other data, we assessed five types of prescribing problems. KEY RESULTS: Among 462,405 patients age 65 and older, mean age was 75 years, 98 % were male, and patients were prescribed a median of five medications. Half of patients (50 %) had one or more prescribing problems, including 12 % taking one or more medications at an inappropriately high dose, 30 % with drug-drug interactions, 3 % with drug-disease interactions, and 26 % taking one or more Beers criteria drugs. In addition, 16 % were taking a high-risk drug (warfarin, insulin, and/or digoxin). On multivariable analysis, age was not strongly associated with four of the five types of prescribing issues assessed (relative risk < 1.3 across age groups), and comorbid burden conferred substantially increased risk only for drug-disease interactions and use of high-risk drugs. In contrast, the number of drugs used was consistently the strongest predictor of prescribing problems. Patients in the highest quartile of medication use had 6.6-fold to12.5-fold greater risk of each type of prescribing problem compared to patients in the lowest quartile (P < 0.001 for each). CONCLUSIONS: The number of medications used is by far the strongest risk factor for each of five types of prescribing problems. Efforts to improve prescribing should especially target patients taking multiple medications.
Authors: Chunliu Zhan; Rosaly Correa-de-Araujo; Arlene S Bierman; Judy Sangl; Marlene R Miller; Stephen W Wickizer; Daniel Stryer Journal: J Am Geriatr Soc Date: 2005-02 Impact factor: 5.562
Authors: Gerda G Fillenbaum; Joseph T Hanlon; Lawrence R Landerman; Margaret B Artz; Heidi O'Connor; Bryan Dowd; Cynthia R Gross; Chad Boult; Judith Garrard; Kenneth E Schmader Journal: Am J Geriatr Pharmacother Date: 2004-06
Authors: Kenneth E Schmader; Joseph T Hanlon; Carl F Pieper; Richard Sloane; Christine M Ruby; Jack Twersky; Susan Dove Francis; Laurence G Branch; Catherine I Lindblad; Margaret Artz; Morris Weinberger; John R Feussner; Harvey Jay Cohen Journal: Am J Med Date: 2004-03-15 Impact factor: 4.965
Authors: Daniel C Malone; Jacob Abarca; Philip D Hansten; Amy J Grizzle; Edward P Armstrong; Robin C Van Bergen; Babette S Duncan-Edgar; Steven L Solomon; Richard B Lipton Journal: J Am Pharm Assoc (2003) Date: 2004 Mar-Apr
Authors: Janice B Schwartz; Kenneth E Schmader; Joseph T Hanlon; Darrell R Abernethy; Shelly Gray; Jacqueline Dunbar-Jacob; Holly M Holmes; Michael D Murray; Robert Roberts; Michael Joyner; Josh Peterson; David Lindeman; Ming Tai-Seale; Laura Downey; Michael W Rich Journal: J Am Geriatr Soc Date: 2018-12-07 Impact factor: 5.562
Authors: Yuan Luo; William K Thompson; Timothy M Herr; Zexian Zeng; Mark A Berendsen; Siddhartha R Jonnalagadda; Matthew B Carson; Justin Starren Journal: Drug Saf Date: 2017-11 Impact factor: 5.606
Authors: Marcia C Mecca; John M Thomas; Kristina M Niehoff; Anne Hyson; Sean M Jeffery; John Sellinger; Adam P Mecca; Peter H Van Ness; Terri R Fried; Rebecca Brienza Journal: J Gen Intern Med Date: 2019-04-10 Impact factor: 5.128
Authors: Diana Jaber; Fabian Vargas; Linh Nguyen; Joanna Ringel; Kate Zarzuela; Mahad Musse; Min Ji Kwak; Emily B Levitan; Mathew S Maurer; Mark S Lachs; Monika M Safford; Parag Goyal Journal: J Card Fail Date: 2021-11-21 Impact factor: 6.592
Authors: Matthew L Maciejewski; Bradley G Hammill; Elizabeth A Bayliss; Laura Ding; Corrine I Voils; Lesley H Curtis; Virginia Wang Journal: Med Care Date: 2017-04 Impact factor: 2.983
Authors: Kristina M Niehoff; Nallakkandi Rajeevan; Peter A Charpentier; Perry L Miller; Mary K Goldstein; Terri R Fried Journal: Pharmacotherapy Date: 2016-05-28 Impact factor: 4.705